Prospective Study of HIV Infection in Hemophiliacs

This study has been completed.
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
Bloodworks (Puget Sound Blood Center)
ClinicalTrials.gov Identifier:
NCT00005309
First received: May 25, 2000
Last updated: February 5, 2016
Last verified: February 2016
  Purpose
To examine mechanisms of individual differences in the progression of HIV infection in hemophiliacs.

Condition
Acquired Immunodeficiency Syndrome
HIV Infections
Blood Disease
Hemophilia A
Hepatitis, Viral, Human
Blood Transfusion
Cytomegalovirus Infections

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by Bloodworks (Puget Sound Blood Center):

Study Start Date: July 1990
Estimated Study Completion Date: March 1995
Detailed Description:

BACKGROUND:

In the late 1980s, hemophiliacs were transfused with a variety of blood products, including large amounts of cryoprecipitate. In comparison to other cohorts, hemophiliacs are CMV(-), resulting in a comparison group for the study of this virus as a potential cofactor. In contrast, non A, non-B hepatitis is common in comparison to other cohorts, and preliminary data prior to 1990 suggested that this chronic disease predisposes to more rapid progression of HIV infection.

DESIGN NARRATIVE:

Disease-free survival rates were determined in HIV-infected hemophiliacs. The effects of co-factors such as intensive transfusion, concomitant cytomegalovirus or chronic NANB hepatitis infection were ascertained. Host-virus interaction was assessed through the use of plasma cultures, specific antibody titers, and markers of immune changes detected by flow cytometry and immune function assays. The immunology of asymptomatic stable infection was investigated. The safety of volunteer donor blood products was determined in seronegative patients exposed to over 50,000 donors yearly and the risk of sexual transmission of HIV to spouses of seropositive patients was monitored.

  Eligibility

Ages Eligible for Study:   up to 100 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
No eligibility criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005309

Sponsors and Collaborators
Bloodworks (Puget Sound Blood Center)
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Investigator: George Gjerset Bloodworks (Puget Sound Blood Center)
  More Information

ClinicalTrials.gov Identifier: NCT00005309     History of Changes
Other Study ID Numbers: 3012  R01HL043512 
Study First Received: May 25, 2000
Last Updated: February 5, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
Communicable Diseases
Cytomegalovirus Infections
HIV Infections
Hematologic Diseases
Hemophilia A
Hepatitis, Viral, Human
Immunologic Deficiency Syndromes
Infection
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
DNA Virus Infections
Digestive System Diseases
Genetic Diseases, Inborn
Hemorrhagic Disorders
Hepatitis
Herpesviridae Infections
Immune System Diseases
Lentivirus Infections
Liver Diseases
RNA Virus Infections
Retroviridae Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases

ClinicalTrials.gov processed this record on April 27, 2016